Page Image

Mantle Cell Lymphoma

The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.

Advertisement
Advertisement
Andrew MorenoPrint | October 2, 2024
The anti-CD19 autologous CAR-T-cell therapy was approved for use in adults with relapsed or refractory disease.
Andrew MorenoMantle Cell Lymphoma | August 23, 2024
The results from a phase I seamless design study are relevant especially to older patients and those with high-risk disease.
Melissa BadamoMantle Cell Lymphoma | July 31, 2024
The study compared treatment response based on prior systemic lines of therapy and prior BTK inhibition in patients with MCL.
Tycel Phillips, MDMantle Cell Lymphoma | June 25, 2024
The 15-month PFS was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.
Yucai Wang, MD, PhDMantle Cell Lymphoma | June 14, 2024
After five and a half years of follow-up, rituximab maintenance significantly improved survival outcomes.
Melissa BadamoMantle Cell Lymphoma | May 30, 2024
Granted under FDA Priority Review, the approval is based on results from the MCL cohort of the TRANSCEND NHL 001 study.
Kami Maddocks, MDMantle Cell Lymphoma | April 3, 2024
Dr. Maddocks hopes that current trials will help us “spring forward” into a chemotherapy-free approach to treating MCL.
Patrick DalyMantle Cell Lymphoma | April 2, 2024
Liso-cel received regulatory acceptances from the US FDA and the Ministry of Health, Labour and Welfare in Japan for FL.
Blood Cancer TalksBlood Cancer Talks | March 20, 2024
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Melissa BadamoMantle Cell Lymphoma | December 18, 2023
Narazaciclib plus ibrutinib regulated signatures associated with DNA repair, P53 signaling, and glycolytic activity.
Michael Wang, MDMantle Cell Lymphoma | December 22, 2023
Progression-free survival was significantly prolonged with the combination compared with a placebo.
Melissa BadamoMantle Cell Lymphoma | December 15, 2023
The trial established the recommended phase II dose of acalabrutinib, venetoclax, and obinutuzumab.
Melissa BadamoMantle Cell Lymphoma | December 16, 2023
Compared to past studies, acalabrutinib plus rituximab improves post-chemotherapy induction CR rates and MRD negativity.
Melissa BadamoMantle Cell Lymphoma | December 15, 2023
The median overall survival was 44.9 months with ibrutinib plus venetoclax versus 38.6 months with ibrutinib plus placebo.
Leah SherwoodMantle Cell Lymphoma | December 14, 2023
The data came from ZUMA-2, a phase II, open-label, multicenter, single-arm trial in which participants received brexu-cel.
Melissa BadamoMantle Cell Lymphoma | December 13, 2023
The study evaluated ROR1 expression levels in a panel of MCL cell lines and primary patient samples.
Kerri FitzgeraldMantle Cell Lymphoma | December 13, 2023
Pirtobrutinib is a non-covalent (reversible) BTK inhibitor that inhibits both wild-type and C481-mutant BTK.
Kerri FitzgeraldMantle Cell Lymphoma | December 15, 2023
Study authors noted that the findings underscore the need for tailored approaches to MRD testing.
Melissa BadamoMantle Cell Lymphoma | December 13, 2023
Jonathon B. Cohen, MD, MS, reported these updated results from the BRUIN trial.
Melissa BadamoMantle Cell Lymphoma | December 6, 2023
Those high-risk disease features include high proliferation index, TP53 mutation, blastoid morphology, and CNS lymphoma.
Patrick DalyAggressive B-Cell Lymphoma | December 13, 2023
After a median of four years of follow-up, participants in the pivotal ZUMA-2 study had a median OS of nof nearly five years.